After seven years of debate, and 19 formal rounds of negotiations, the Trans-Pacific Partnership was agreed in October this year. Its IP provisions, which are among the most controversial, will have an impact on pharmaceutical protection, copyright, trade marks, geographical indications and enforcement, among other areas. Peter Leung provides a summary of the main points and over the following pages we look at the impact country-by-country
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Leaders at the IP firms, which have joined forces with backing from a PE investor, share their vision of building the number one pan-European IP practice
The opinion provides useful guidance when it comes to how courts might consider contributory infringement, DMCA claims, and other issues in AI copyright cases